Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 1.81% | 174.66 | 1.2% | $575.79m | |
| CELG | Celgene Corporation | 0.60% | 89.49 | 1.2% | $535.84m | |
| GILD | Gilead Sciences, Inc. | 0.42% | 74.01 | 0.9% | $421.63m | |
| BIIB | Biogen Inc. | -1.41% | 259.30 | 1.2% | $416.64m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.56% | 316.01 | 2.7% | $245.42m | |
| INCY | Incyte Corporation | -0.42% | 68.14 | 2.5% | $245.05m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.34% | 158.69 | 1.9% | $226.49m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.05% | 107.83 | 2.0% | $209.17m | |
| NKTR | Nektar Therapeutics | -0.88% | 85.45 | 6.0% | $201.71m | |
| ILMN | Illumina, Inc. | 0.51% | 245.85 | 3.5% | $184.02m | |
| A | Agilent Technologies, Inc. | 0.74% | 68.05 | 1.5% | $157.16m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -1.66% | 95.86 | 9.8% | $140.19m | |
| BLUE | Bluebird Bio, Inc. | -1.32% | 168.25 | 15.8% | $127.75m | |
| EXAS | Exact Sciences Corporation | 2.48% | 48.70 | 25.7% | $111.34m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.27% | 82.08 | 4.4% | $104.77m |
Company Profile
Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.